作为协议的一部分，葛兰素史克不承认存在不当行为，并在一份声明中表示，“没有一致或可靠的证据”表明该药的活性成分雷尼替丁(ranitidine ...

葛兰素史克 在美国州法院Zantac案件中达成高达22亿美元的和解协议。 葛兰素史克公司周三表示，已与10家原告公司达成协议，这些公司占美国州法院 ...

(Bloomberg) -- GSK Plc is facing a whistleblower lawsuit that could potentially cost it billions of dollars from the laboratory that revealed the presence of a probable carcinogen in Zantac, the ...

(Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued ...

The FDA banned sales of ranitidine in 2020 over possible contamination with the suspected carcinogen N-nitrosodimethylamine (NDMA. Some manufacturers of the drug voluntarily suspended sales in ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

(WJET/WFXP) — UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now ...